Form 4: LENSAR Director Richard Lindstrom Receives Annual Equity Compensation Grant

LENSAR, Inc. Director Richard L. Lindstrom, MD, was granted 7,374 Restricted Stock Units as part of his annual compensation, vesting on May 23, 2026.

Summary

• Director Richard L. Lindstrom, MD, acquired 7,374 shares of LENSAR, Inc. common stock on May 23, 2025.
• These shares were granted as Restricted Stock Units (RSUs) with an acquisition price of $0, indicating a grant rather than a purchase.
• The RSUs are scheduled to vest in full on May 23, 2026, contingent upon Dr. Lindstrom's continued service to the Issuer.
• The grant is a component of the company's non-employee director compensation program.
• Following this transaction, Dr. Lindstrom beneficially owns a total of 246,410 shares of LENSAR, Inc. common stock.

Sentiment

Score: 7

Explanation: The filing indicates a routine and positive corporate governance action where a director receives equity compensation, aligning their interests with the company's long-term performance. There are no negative or unexpected elements present in this standard compensation grant.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns their long-term interests with those of the shareholders, promoting sustained commitment to the company's success.
• This transaction is part of a standard, established non-employee director compensation program, indicating stable and predictable corporate governance practices.

Risks

• The vesting of the 7,374 Restricted Stock Units is subject to the director's continued service to LENSAR, Inc. through May 23, 2026, meaning the shares are not immediately owned and could be forfeited if service terminates prior to the vesting date.

Future Outlook

The granted Restricted Stock Units are scheduled to vest in full on May 23, 2026, contingent upon the director's continued service, representing a future milestone for this equity compensation.

Management Comments

• "The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer."

Industry Context

This transaction reflects a common practice in publicly traded companies, particularly in the medical technology and healthcare sectors, where equity-based compensation like Restricted Stock Units (RSUs) is used to incentivize non-employee directors and align their interests with long-term shareholder value.

Comparison to Industry Standards

• Granting Restricted Stock Units (RSUs) as part of non-employee director compensation is a widely adopted practice across various industries, including medical devices and ophthalmology, serving to align director incentives with company performance and shareholder interests.
• The specified vesting schedule (full vesting one year from the grant date) is typical for annual equity grants to non-executive directors, promoting retention and sustained commitment.
• Companies comparable to LENSAR, Inc. in the ophthalmic device sector, such as Alcon (ALC) or Carl Zeiss Meditec (AFX.DE), frequently employ similar equity-based compensation structures for their non-executive board members.

Corporate Governance

Related Party Transactions

• Grant of 7,374 Restricted Stock Units (RSUs) to Richard L. Lindstrom, MD, a director of LENSAR, Inc., as part of his annual compensation for service to the Issuer.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their financial interests with the company's long-term performance, potentially encouraging decisions that enhance shareholder value.
• Management: No direct impact on management operations or structure is indicated by this compensation grant.

Next Steps

• The 7,374 Restricted Stock Units are scheduled to vest on May 23, 2026, subject to the director's continued service to LENSAR, Inc.

Key Dates

Recommendation

Keywords

LENSAR, LNSR, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership, Corporate Governance